Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 42

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 42
---
 in open market transactions at an average price of $69.59 and $66.71 per share, respectively, for aggregate purchase prices of $42.5 million and $172.9 million, respectively. As of September 30, 2025, $11.4 million of the current authorization remained available for the repurchase of shares of our common stock.We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of September 30, 2025 and December 31, 2024, we had 36.0 million and 32.6 million treasury shares outstanding, respectively.Incentive Award PlanWe have one equity award plan – the Corcept Therapeutics Incorporated 2024 Incentive Award Plan (the “2024 Plan”).Stock OptionsDuring the three and nine months ended September 30, 2025, we issued 0.5 million and 2.4 million, respectively, shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three and nine months ended September 30, 2025, we purchased 0.1 million and 0.6 million shares, respectively, in connection with option net exercises and paid $4.0 million and $24.6 million, respectively, to satisfy associated tax withholding obligations.During the three and nine months ended September 30, 2024, we issued 1.0 million and 1.8 million, respectively, shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them at the then current market price shares equal in value to the associated exercise price and tax withholding obligations. During the three and nine months ended September 30, 2024, we 

14

purchased 0.5 million and 0.8 million shares, respectively, in connection with option net exercises and paid $10.5 million and $12.2 million, respectively, to satisfy associated tax withholding obligations.Restricted Stock Awards (“RSAs”) and Restricted Stock Units (“RSUs”)During the three and nine months ended September 30, 2025, we granted employees